Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. The company is headquartered in Lexington, Massachusetts.
| Revenue (TTM) | $7.06M |
| Gross Profit (TTM) | $-19.13M |
| EBITDA | $-34.11M |
| Operating Margin | -485.10% |
| Return on Equity | -694.00% |
| Return on Assets | -62.10% |
| Revenue/Share (TTM) | $8.89 |
| Book Value | $6.35 |
| Price-to-Book | 1.06 |
| Price-to-Sales (TTM) | 1.36 |
| EV/Revenue | 36.32 |
| EV/EBITDA | 0.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -66.00% |
| Shares Outstanding | $1.95M |
| Float | $1.63M |
| % Insiders | 8.03% |
| % Institutions | 40.50% |
Volatility is currently expanding
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study.
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected December 2026; Stockholders approve reverse stock split LEXINGTON, Mass., June 26, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that eleven clinical sites have been initiated and are now open for patient enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib in combination with zanubrutinib in patients with Chronic Lymphocytic Leukemia.
Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago.
Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
